| Unique ID issued by UMIN | UMIN000057798 |
|---|---|
| Receipt number | R000065849 |
| Scientific Title | Real-World Evidence (RWE) Retrospective Chronic Obstructive Pulmonary Disease (COPD) Study among Users of Heated Tobacco Products (HTPs) Diagnosed with COPD Compared to Cigarettes (CIG) Smokers and Former Smokers in Japan |
| Date of disclosure of the study information | 2025/05/09 |
| Last modified on | 2026/11/09 11:11:52 |
Real-World Evidence (RWE) Retrospective Chronic Obstructive Pulmonary Disease (COPD) Study among Users of Heated Tobacco Products (HTPs) Diagnosed with COPD Compared to Cigarettes (CIG) Smokers and Former Smokers in Japan
RWE Retrospective COPD Study in heated tobacco product users and cigarette smokers diagnosed with COPD
Real-World Evidence (RWE) Retrospective Chronic Obstructive Pulmonary Disease (COPD) Study among Users of Heated Tobacco Products (HTPs) Diagnosed with COPD Compared to Cigarettes (CIG) Smokers and Former Smokers in Japan
RWE Retrospective COPD Study in heated tobacco product users and cigarette smokers diagnosed with COPD
| Japan |
Chronic Obstructive Pulmonary Disease (COPD)
| Pneumology |
Others
NO
The purpose of the study is to retrospectively evaluate the impact of having switched from CIG to exclusive use of HTPs (hereafter, exclusive HTP use) on the time to first subsequent COPD-related hospitalization or all-cause mortality compared with continued smoking of CIG (hereafter, exclusive CIG smoking), dual use of CIG and HTP, and quitting of CIG (hereafter, former CIG smoking) among patients who experienced a COPD-related hospitalization (Index Event), after adjusting for sociodemographic and other risk factors.
Others
The primary outcome is about comparative effectiveness.
Not applicable
To compare the time from Index Event to a first subsequent COPD-related hospitalization or all-cause mortality between comparable groups of exclusive HTP users and exclusive CIG smokers.
-Index Event defined as a first COPD-related hospitalization between 1st May 2016 and 31st December 2022.
-The composite endpoint defined as (whichever comes first):
-First subsequent COPD-related hospitalization
-All-cause mortality
1.To compare the time from Index Event to all-cause mortality between comparable groups of i) exclusive HTP users versus exclusive CIG smokers, ii) exclusive HTP users versus former smokers, and iii) exclusive HTP users versus dual users of CIG and HTP.
Endpoint:
-All-cause mortality
2.To compare the time from Index Event to a first pneumonia-related hospitalization between comparable groups of i) exclusive HTP users versus exclusive CIG smokers, ii) exclusive HTP users versus former smokers, and iii) exclusive HTP users versus dual users of CIG and HTP.
Endpoint:
-Pneumonia-related hospitalization
3.To compare the number and rate of recurrent COPD-related hospitalizations and all-cause hospitalization per year accounting for death as competing risk from Index Event by comparable tobacco exposure groups (exclusive HTP users, dual users of HTP and CIG, and former smokers).
Endpoints:
-Rate and number of COPD-related hospitalizations for each year post-index during the entire observation period
-All-cause hospitalizations for each year post-index during the entire observation period
4.To compare the time from Index Event to the composite endpoint defined above (first subsequent COPD-related hospitalization or all-cause mortality) between comparable groups of i) exclusive HTP users versus former smokers and ii) exclusive HTP users versus dual users of CIG and HTP.
Endpoint:
Composite endpoint defined as (whichever comes first):
-First subsequent COPD-related hospitalization
-All-cause mortality
5.To evaluate whether the time from Index Event to a first subsequent COPD-related hospitalization or all-cause mortality for exclusive HTP users vs exclusive CIG smokers varies for exclusive HTP users by the number of years of switching (<1 year, 1-3 years, >3 years).
Endpoint:
Composite endpoint defined as (whichever comes first):
-First subsequent COPD-related hospitalization
-All-cause mortality
Observational
| 40 | years-old | <= |
| Not applicable |
Male and Female
-Patients with any healthcare encounter records in the Tokushukai Medical Database
-Patients with a record of Index Event (first COPD-related hospitalization between the 1st of May 2016 and the 31st of December 2022)
-Age 40 year or older at the time of the Index Event
-Patients of any gender
-Patients or relatives who are able to understand the information provided in the ICF and have signed it.
-Tobacco industry employees or their first-degree relatives
-Employees of Philip Morris International (PMI) and its affiliate companies, Tokushukai Medical Corporation, 3H Medi Solution, or Syneos Health Clinical K.K.
-Patients who have had five or more COPD-related hospitalizations in the 12 months prior to the Index Event
-Never smokers (this population was excluded because the prevalence of never smoking is extremely low among COPD patient population).
-Patients having any of the following diseases prior to the Index Event: bronchiectasis, active tuberculosis (defined as a tuberculosis diagnosis in the 12 months prior to Index Event), cystic fibrosis, pulmonary fibrosis, pulmonary embolism, lung cancer.
9638
| 1st name | Makoto |
| Middle name | |
| Last name | Hibino |
Tokushukai Medical Corporation Shonan-Fujisawa Tokushukai Hospital
Respiratory Medicine
251-0041
1-5-1 Tsujidokandai, Fujisawa-shi, Kanagawa, Japan
0466-35-1177
m-hibino@ctmc.jp
| 1st name | Takashi |
| Middle name | |
| Last name | Sato |
Syneos Health Clinical K.K.
Clinical Operations/Real World and Late Phase
100-7012
12F JP Tower, 2-7-2 Marunouchi, Chiyoda-ku, Tokyo, Japan
03-6733-9690
takashi.sato@syneoshealth.com
Philip Morris Products S.A.
Philip Morris Products S.A.
Profit organization
Switzerland
The Tokushukai Group Ethics Committee
Tokyodo Chiyoda Bldg. 15F, 1-3-1, Kudan-minami, Chiyoda-ku, Tokyo, Japan
03-3263-4801
mirai-ec1@mirai-iryo.com
NO
徳洲会グループ/ Tokushukai Group
| 2025 | Year | 05 | Month | 09 | Day |
Not applicable.
Unpublished
Not applicable.
2298
Of the 2,298 patients who signed the informed consent form, 1,305 met the eligibility criteria and were included in the study. Among the 1,305 patients, 236 (18.1%) were exclusive cigarette (CIG) smokers, 24 (1.8%) were exclusive HTP users, 12 (0.9%) were dual users of CIG and HTPs, and 1,033 (79.2%) were former smokers at the date of Index Event, defined as the discharge date of an initial COPD-related hospitalization.
| 2026 | Year | 09 | Month | 07 | Day |
Not applicable. There were no delays in result reporting.
Among the 1,305 patients included in the study, 236 (18.1%) were exclusive CIG smokers, 24 (1.8%) were exclusive HTP users, 12 (0.9%) were dual users of CIG and HTP, and 1,033 (79.2%) were former smokers. Most of the questionnaire data was self-reported by the patients themselves (68.0%, n=888).
The median age at the date of Index Event was 75.0 years (Q1: 69.0, Q3: 82.0). By tobacco exposure groups, the median age was 72 years (Q1: 64.0, Q3: 78.0) for exclusive CIG smokers, 66 years (Q1: 56.5, Q3: 74.0) for exclusive HTP users, 65.5 years (Q1: 52.0, Q3: 75.5) for dual users of CIG and HTP, and 76 years (Q1: 70.0, Q3: 83.0) for former smokers in the unadjusted (unweighted) analysis.
A total of 1,162 (89%) patients were males. The median pack-years of CIG smoking prior to index for all exposure groups combined was 50.8 (Q1: 30.0, Q3: 73.5). Among the exposure groups, the median pack-years of CIG smoking prior to index was 47.9 (Q1: 31.9, Q3: 78.0) in the exclusive CIG smokers, 35.9 (Q1: 28.5, Q3: 55.8) in the exclusive HTP users, 52.5 (Q1: 36.3, Q3: 87.8) in the dual users of CIG and HTP, and 52.5 (Q1: 29.0, Q3: 72.0) in the former smokers in the unadjusted (unweighted) analysis.
A total of 29,580 potentially eligible patients (including those deceased) were identified in the Tokushukai Medical Database. They were contacted by post to probe their interest in participating in the study. Of those, 2,298 patients consented (either personally or through a relative / legal guardian) to participate in the study and were enrolled into the study. Of the enrolled patients, 1,305 met all eligibility criteria and were included in the study. A total of 993 patients were not included in the study for the following reasons:
18 patients had inaccurate assessment of eligibility criteria,
554 patients were excluded from the analysis as they could not be assigned to any tobacco exposure group due to missing information from the questionnaires.
421 patients were classified as never smokers at the date of Index Event, thus not meeting the eligibility criteria.
Not applicable. This was a retrospective cohort study, with no active follow-up of patients. Therefore, no information on adverse events was collected.
Primary (Main) Outcome: time between first chronic obstructive pulmonary disease (COPD)-related hospitalization and subsequent COPD-related hospitalization or all-cause mortality.
Of the 2,298 patients who signed the informed consent form, 1,305 met the eligibility criteria and were included in the study. Among the 1,305 patients, 236 (18.1%) were exclusive cigarette (CIG) smokers, 24 (1.8%) were exclusive HTP users, 12 (0.9%) were dual users of CIG and HTPs, and 1,033 (79.2%) were former smokers at the date of Index Event, defined as the discharge date of an initial COPD-related hospitalization.
Exclusive CIG smoking was defined as smoking at least one CIG per day on average and no use of HTPs, or using less than one HTP consumable per day, at the date of the Index Event. Exclusive HTP use was defined as the use of at least one HTP consumable per day on average with no CIG smoking, or smoking less than one CIG per day, at the date of the Index Event.
The analysis was descriptive, as the number of patients in the different tobacco exposure groups was low. This precluded hypothesis testing and comparative analyses of the composite endpoint between exposure groups.
The unadjusted median follow-up time was 1.71 years (Q1: 0.22, Q3: 3.82) overall, 1.07 years (Q1: 0.15, Q3: 2.97) among exclusive HTP users, and 0.97 years (Q1: 0.13, Q3: 3.34) among exclusive CIG smokers.
Overall, 499 patients (38.2%) had a first subsequent COPD-related hospitalization or all-cause mortality during follow-up, including 5 of 24 exclusive HTP users (20.8%) and 76 of 236 exclusive CIG smokers (32.2%). The unadjusted median time to the composite endpoint was 8.9 months for exclusive HTP users and 5.3 months for exclusive CIG smokers.
Propensity score weighting was applied to adjust for age, sex, and length of the COPD-related hospitalization at the date of Index Event. Due to the sample size limitations, only these variables could be selected for statistical adjustment, and those variables were appraised to be the most relevant.
The weighted percentage of patients without the composite endpoint at the end of Year 1 of follow-up was 82% (95% confidence interval [CI]: 53.5, 93.9) for exclusive HTP users and 76.4% (68.2, 82.7) for exclusive CIG smokers. By Year 5, only two patients in each exposure group were still without the composite endpoint or uncensored, patients remaining under observation.
Secondary Outcomes
Time until the all-cause mortality between HTP users and all other tobacco exposure groups
Among the 1,305 patients, 329 (25.2%) died during the follow-up period, 68 (28.8%) of whom were exclusive CIG smokers, 1 (4.2%) exclusive HTP user, 3 (25.0%) dual users of CIG and HTP, and 257 (24.9%) former smokers. The low number of events among the HTP user group precluded any further analysis for this endpoint.
Time until pneumonia-related hospitalization between HTP users and all other tobacco exposure groups
One of 24 (4.2%) exclusive HTP users experienced pneumonia-related hospitalization during the follow-up period. Due to the low event count, estimation of cumulative incidence was not feasible. Nineteen of 236 (8.1%) exclusive CIG smokers, 1 of 12 (8.3%) dual users of HTP and CIG, and 164 of 1,033 (15.9%) former smokers experienced pneumonia-related hospitalization during the follow-up period.
Rate of recurrent COPD-related hospitalizations per year
The rate for recurrent COPD-related hospitalizations, weighted for age, sex, and length of the COPD-related hospitalization at the date of Index Event, was 1.03 per 10 person-years (95% CI: 0.43, 2.48) among exclusive HTP users, 1.37 per 10 person-years (95% CI: 0.29, 6.44) among dual users of CIG and HTP, 1.75 per 10 person-years (95% CI: 1.31, 2.36) among exclusive CIG smokers, and 2.01 per 10 person-years (95% CI: 1.81, 2.23) among former smokers.
Rate of recurrent all-cause hospitalizations per year
The rate for recurrent all-cause hospitalizations, weighted for age, sex, and length of the COPD-related hospitalization at the date of Index Event, was 3.42 per 10 person-years (95% CI: 1.93, 6.05) among exclusive HTP users, 4.40 per 10 person-years (95% CI: 3.52, 5.50) among exclusive CIG smokers, 4.58 per 10 person-years (95% CI: 1.17, 17.94) among dual users of CIG and HTP, and 4.59 per 10 person-years (95% CI: 4.27, 4.94) among former smokers.
Composite endpoint of first subsequent COPD-related hospitalization or all-cause mortality comparing exclusive HTP users with other tobacco exposure groups
Prior to propensity score weighting, the composite endpoint was observed in 2 of 12 (16.7%) dual users of CIG and HTP, and 416 of 1,033 (40.3%) former smokers. The limited number of events among the dual users of CIG and HTP group precluded any further analysis.
Regarding exclusive HTP users and former smokers, the unadjusted median time to the composite endpoint was 8.9 months for exclusive HTP users and 12.2 months for former smokers. Time-to-event estimates, weighted for age, sex, and length of the COPD-related hospitalization at the date of Index Event, for exclusive HTP users and former smokers had wide and overlapping 95% CI indicative of the small number of exclusive HTP users and the low number of events.
The analysis on whether the time from Index Event to subsequent COPD-related hospitalization or all-cause mortality for exclusive HTP users versus exclusive CIG smokers varies by the number of years of HTP use could not be performed due to the low number of enrolled exclusive HTP users.
The study sponsor is committed to transparency and will consider any requests for underlying data, provided that such data may be shared under applicable laws.
Refer to the section "Plan to share IPD."
Completed
| 2024 | Year | 08 | Month | 06 | Day |
| 2024 | Year | 08 | Month | 13 | Day |
| 2024 | Year | 12 | Month | 09 | Day |
| 2025 | Year | 04 | Month | 30 | Day |
| 2025 | Year | 06 | Month | 30 | Day |
| 2025 | Year | 08 | Month | 31 | Day |
| 2025 | Year | 12 | Month | 29 | Day |
It is expected that there will be a difference in the time from Index Event to a first subsequent COPD-related hospitalization and all-cause mortality between smokers who switched to exclusive use of HTP and those that continued to smoke CIG exclusively. The findings on the time from Index Event to a first subsequent COPD-related hospitalization and all-cause mortality in exclusive HTP users compared to dual users of CIG and HTP and former smokers will also be reported. The results of the study will be released in the first quarter of 2026.
| 2025 | Year | 05 | Month | 08 | Day |
| 2026 | Year | 11 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000065849